Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now
¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.
Important UpdateActualización importante:
Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Change in Preferred Drug List Status for Glucocorticoids, Inhaled Drug Class
Date: May 12, 2025
Attention: Prescribers
Effective date: May 6, 2025
Call to action: Due to the shortage, Health and Human services Commission (HHSC) removed the non-preferred status of the drugs in the table below from the authorized generic (AG) fluticasone HFA products on the preferred drug list (PDL), effective May 6, 2025.
Background: The manufacturers of brand-name Asmanex HFA, Organon, and QVAR RediHaler, Teva
Pharmaceuticals, reported product backorders due to distribution and manufacturing delays.
How this impacts providers: These changes allow providers to prescribe the AG fluticasone HFA products without requiring a PDL prior authorization and continue access to necessary asthma control medications for members.
NDC
Drug Name
66993-0078-96
FLUTICASONE PROP HFA 44 MCG
66993-0079-96
FLUTICASONE PROP HFA 110 MCG
66993-0080-96
FLUTICASONE PROP HFA 220 MCG
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
If you have any questions, please email Provider Relations at tchppharmacy@texaschildrens.org.
